Vaxart granted Nasdaq extension; must complete reverse stock split by Oct 6, regain $1 bid price by Oct 17

Vaxart, Inc.

Nasdaq Hearings Panel decision on Aug 27, 2025 grants continued listing with three conditions.
Shareholder approval for reverse stock split required by Sep 5, 2025 special meeting.
Reverse stock split must be completed by Oct 6, 2025; bid price compliance by Oct 17, 2025.
Failure to obtain RSS approval will result in delisting per the Panel's decision.
Vaxart engaged in stockholder outreach; management emphasizes RSS vote for Nasdaq future.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.